Medication info
Ambildagliptin 50 mg (Dapagliflozin)

Ambildagliptin 50 mg (Dapagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tablet
Manufacturer / importer
McNulty Pharmaceuticals Co., Ltd.
Appearance
White to pale yellow circular tablet
Packaging
28 tablets/box [14 tablets/PTP (x2)]
Approval status
Active

MFDS item code 202200087 · Approved 2022.01.04 · Insurance code 641502770

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine may be administered as monotherapy or, in patients with no previous experience of antidiabetic drug therapy, in combination with metformin at a dose of 50mg once daily in the morning or 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with metformin or thiazolidinedione monotherapy, the recommended dose when this medicine is used in combination with metformin or a thiazolidinedione is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with sulfonylurea monotherapy, the recommended dose when this medicine is used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, once-daily administration of vildagliptin 100mg was not more effective than administration of 50mg once daily. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose when this medicine is added (as triple therapy) is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose when this medicine is added is 100mg per day, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food, and doses greater than 100mg per day are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia. If you miss a dose of this medicine, take it as soon as you remember and take the next dose at your usual time. If you remember when it is nearly time for your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal. Patients with renal impairment Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is required. Moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (Refer to item 2) under “3. General Precautions” in the Precautions for Use.)

Ingredients

Manufacturer
McNulty Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Difficulty in blood sugar control
View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes. It can be administered alone as initial therapy, and if blood sugar control is difficult with monotherapy, it can be taken in combination with metformin. Additionally, this drug can be combined when blood sugar control is insufficient with single therapy using sulfonylurea, metformin, or thiazolidinedione. If blood sugar control is still inadequate after combination therapy of sulfonylurea and metformin, this medication may be added, and it can also be administered in conjunction with insulin solo or in combination with insulin and metformin if blood sugar control is inadequate. This medication aids in the safe and effective management of diabetes tailored to various combination therapies and situations.

How to take

Adult dose

This medicine may be administered as monotherapy or, in patients with no previous experience of antidiabetic drug therapy, in combination with metformin at a dose of 50mg once daily in the morning or 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with metformin or thiazolidinedione monotherapy, the recommended dose when this medicine is used in combination with metformin or a thiazolidinedione is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with sulfonylurea monotherapy, the recommended dose when this medicine is used in combination with a sulfonylurea is 50mg once daily in the morning. In this patient group, once-daily administration of vildagliptin 100mg was not more effective than administration of 50mg once daily. When adequate glycemic control cannot be achieved with combination therapy of a sulfonylurea and metformin, the recommended dose when this medicine is added (as triple therapy) is 100mg per day, divided into 50mg twice daily in the morning and evening. When adequate glycemic control cannot be achieved with insulin therapy (insulin alone or in combination with metformin), the recommended dose when this medicine is added is 100mg per day, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food, and doses greater than 100mg per day are not recommended. When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia. If you miss a dose of this medicine, take it as soon as you remember and take the next dose at your usual time. If you remember when it is nearly time for your next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels before treatment exceed 2.5 times the upper limit of normal. Patients with renal impairment Mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is required. Moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (Refer to item 2) under “3. General Precautions” in the Precautions for Use.)

Precautions

This medication should not be used in patients with allergies to the active ingredient or other ingredients. It should also not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Since it contains lactose, patients with lactose intolerance or related genetic issues should avoid use. This drug can cause liver dysfunction; therefore, regular liver function tests should be conducted before and during treatment. If liver function levels rise to more than three times the upper limit of normal, treatment should be discontinued. There is a risk of acute pancreatitis; thus, if symptoms of pancreatitis appear, the use of this medication should be stopped immediately. As there is a risk of hypoglycemia, caution is needed when used, particularly with sulfonylurea drugs. Symptoms such as dizziness or headaches may occur, so care should be taken when driving or operating machinery. If there are severe joint pain or abnormal skin symptoms such as blisters, ulcers, etc., you should consult a physician immediately. Pregnant or breastfeeding women should avoid using this medication, and it is not recommended for children under 18. Use should be cautious in patients with end-stage renal disease, and no dose adjustment is required for the elderly. In cases of overdose, since there is no specific antidote, symptomatic supportive treatment is necessary. Store away from children, and do not transfer to another container.

Side effects

  • Hepatitis
  • impaired liver function
  • elevated transaminase levels
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
  • nausea
  • hypoglycemia
Show 65 more
  • pharyngitis
  • asthenia
  • constipation
  • weight gain
  • peripheral edema
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • decreased blood sugar
  • hyperhidrosis
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • severe and disabling arthralgia
  • cutaneous vasculitis
  • cholecystitis
  • upper respiratory tract infection
  • acute myocardial infarction
  • nodular arrhythmia
  • acute cholecystitis
  • pneumothorax
  • cholelithiasis
  • femoral fracture
  • peripheral artery obstruction disease
  • supraventricular tachycardia
  • congestive heart failure
  • gastric ulcer
  • gastric cancer
  • increased INR
  • appendicitis
  • pulmonary edema
  • dizziness
  • chest discomfort
  • dyspnea
  • cough
  • dyspepsia
  • drowsiness
  • pruritus
  • dry mouth
  • vomiting
  • insomnia
  • renal impairment
  • lip blisters
  • hunger
  • sensory impairment
  • spinal canal stenosis
  • abdominal pain
  • gastroenteritis
  • gastritis
  • gastric ulcer
  • belching
  • fatty liver
  • hyperkalemia
  • hypertriglyceridemia
  • heart failure
  • cardiomegaly
  • angina
  • cardiac arrest
  • renal cyst
  • lung neoplasm
  • leg pain
  • increased C-reactive protein
  • vesicular pemphigoid

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, preferably in a cool place below 30 degrees Celsius. Proper storage helps maintain the drug's efficacy over time.

Appearance and packaging

Appearance

White to pale yellow circular tablet

Package unit

28 tablets/box [14 tablets/PTP (x2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.